← Leaderboards
Michelle A Ozbun
University Of New Mexico
$12,598,817
Attributed
$12,598,817
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,598,817 · 16
By mechanism
R01$5,099,309 · 4
U19$2,786,252 · 2
T32$2,626,379 · 1
R21$1,546,130 · 4
P30$478,074 · 2
P51$62,673 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusVirionGenetic TranscriptionInfectionCellsMalignant NeoplasmsEpitheliumBiologyMolecularAffectGene ExpressionTissuesProgramsKeratinocyteViralHuman Papillomavirus 16VirusHuman Papilloma Virus InfectionSignal TransductionInnovationIn VivoLaboratoriesPapillomavirus InfectionsReporting
Grant awards (55)
Mechanisms of Papillomavirus Tumor Regression by MEK Signaling Inhibition$544,768
R01 · FY2025 · CA · contact PI
Development of a novel anti-viral treatment for persistent HPV disease$224,630
R21 · FY2025 · AI · contact PI
Cellular and Molecular Oncology$119,560
P30 · FY2025 · CA · contact PI
Biology of Infectious Disease and Inflammation$296,381
T32 · FY2024 · AI · contact PI
Development of a novel anti-viral treatment for persistent HPV disease$190,625
R21 · FY2024 · AI · contact PI
Cellular and Molecular Oncology$119,560
P30 · FY2024 · CA · contact PI
Biology of Infectious Disease and Inflammation$299,398
T32 · FY2023 · AI · contact PI
Cellular and Molecular Oncology$119,561
P30 · FY2023 · CA · contact PI
Biology of Infectious Disease and Inflammation$281,124
T32 · FY2022 · AI · contact PI
Cellular and Molecular Oncology$119,393
P30 · FY2022 · CA · contact PI
Mechanisms of Infection by Oncogenic HPVs$345,867
R01 · FY2021 · CA · contact PI
Biology of Infectious Disease and Inflammation$297,264
T32 · FY2021 · AI · contact PI
Mechanisms of Infection by Oncogenic HPVs$345,887
R01 · FY2020 · CA · contact PI
Biology of Infectious Disease and Inflammation$298,025
T32 · FY2020 · AI · contact PI
Sex-based differences in oral HPV infections and outcomes$189,375
R21 · FY2020 · DE · contact PI
Mechanisms of Infection by Oncogenic HPVs$335,528
R01 · FY2019 · CA · contact PI
Sex-based differences in oral HPV infections and outcomes$227,250
R21 · FY2019 · DE · contact PI
Mechanisms of Infection by Oncogenic HPVs$345,925
R01 · FY2018 · CA · contact PI
Biology of Infectious Disease and Inflammation$234,357
T32 · FY2018 · AI · contact PI
Mechanisms of Infection by Oncogenic HPVs$345,944
R01 · FY2017 · CA · contact PI
Biology of Infectious Disease and Inflammation$133,180
T32 · FY2017 · AI · contact PI
Biology of Infectious Disease and Inflammation$279,487
T32 · FY2016 · AI · contact PI
Biology of Infectious Disease and Inflammation$271,197
T32 · FY2015 · AI · contact PI
Targeted Therapy for EGFR Pathway in HPV+ HNSCCs$226,500
R21 · FY2015 · DE · contact PI
Biology of Infectious Disease and Inflammation$235,966
T32 · FY2014 · AI · contact PI
Targeted Therapy for EGFR Pathway in HPV+ HNSCCs$188,750
R21 · FY2014 · DE · contact PI
Virion Production and Infection Assay Core$301,464
U19 · FY2013 · AI · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$283,799
R01 · FY2013 · CA · contact PI
Genital Papillomavirus Infections in Epithelial Tissues$282,022
U19 · FY2013 · AI · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$47,390
R01 · FY2013 · CA · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$301,913
R01 · FY2012 · CA · contact PI
Genital Papillomavirus Infections in Epithelial Tissues$237,198
U19 · FY2012 · AI · contact PI
Virion Production and Infection Assay Core$153,076
U19 · FY2012 · AI · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$31,487
R01 · FY2012 · CA · contact PI
Genital Papillomavirus Infections in Epithelial Tissues$331,794
U19 · FY2011 · AI · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$301,913
R01 · FY2011 · CA · contact PI
Virion Production and Infection Assay Core$204,135
U19 · FY2011 · AI · contact PI
Genital Papillomavirus Infections in Epithelial Tissues$369,421
U19 · FY2010 · AI · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$311,250
R01 · FY2010 · CA · contact PI
Virion Production and Infection Assay Core$288,813
U19 · FY2010 · AI · contact PI
Entry of Oncogenic HPVs into Human Keratinocytes$350,449
R01 · FY2009 · CA · contact PI
Virion Production and Infection Assay Core$312,808
U19 · FY2009 · AI · contact PI
Genital Papillomavirus Infections in Epithelial Tissues$305,521
U19 · FY2009 · AI · contact PI
HPV INFECTIVITY & PERSISTENCE IN EXPERIMENTALLY INFECTED FEMALE RHESUS MACAQUES$34,816
P51 · FY2009 · RR · contact PI
RHPV INFECTIVITY & PERSISTENCE IN EXPERIMENTALLY INFECTED FEMALE RHESUS MACAQUES$13,897
P51 · FY2008 · RR · contact PI
RHPV INFECTIVITY & PERSISTENCE IN EXPERIMENTALLY INFECTED FEMALE RHESUS MACAQUES$13,960
P51 · FY2007 · RR · contact PI
RhPV1 a Model of HPV-Induced Anogenital Malignancies$150,000
R21 · FY2005 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$231,525
R01 · FY2004 · CA
RhPV1 a Model of HPV-Induced Anogenital Malignancies$149,000
R21 · FY2004 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$40,574
R01 · FY2004 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$25,064
R01 · FY2004 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$227,718
R01 · FY2003 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$227,718
R01 · FY2002 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$227,295
R01 · FY2001 · CA
HUMAN PAPILLOMAVIRUS SYNTHESIS &EARLY INFECTION EVENTS$227,295
R01 · FY2000 · CA